Detection of a common mutation in factor V gene responsible for resistance to activated protein C causing predisposition to thrombosis

Journal of Clinical Laboratory Analysis

Volumn 11, Issue 6, 1997, Pages 328-335

  Ferreira Gonzalez, A ^a   Fisher, L M ^a   Lehman, C M ^a   Langley, M H ^a   Lofland, D H ^a   Xia, Q ^a   Nguyen, N X ^a   Modesto, D ^a   Willoughby, J B ^a   Wilkinson, D S ^a   Garrett, C T ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APCR; Hereditary activated protein C resistance; Hereditary thrombosis; RFLP PCR

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; DNA;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE RESISTANCE; ETHNIC GROUP; GENETIC PREDISPOSITION; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOSIS;

AFRICAN CONTINENTAL ANCESTRY GROUP; DNA; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FACTOR V; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MUTATION; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTEIN C; SENSITIVITY AND SPECIFICITY; THROMBOSIS;

EID: 9844262801     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2825(1997)11:6<328::AID-JCLA3>3.0.CO;2-1     Document Type: Article

References (38)

1. Weinmann EE, Salzman EW: Deep-Vein Thrombosis. N Engl J Med 331:1630-1641, 1994.
2. Dahlback B: Molecular genetics of thrombophilia: Factor V gene mutation causing resistance to activated protein C as a basis of the hypercoagulable state. J Lab Clin Med 125:566-571, 1995.
3. Dahlback B: Inherited resistance to activated protein C, a major basis of venous thrombosis, is caused by deficient anticoagulant cofactor function of factor V. Haematologica 80:(2Suppl):102-113, 1995.
4. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B: Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 85:3518-3523, 1995.
5. Dahlback B: Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism. J Intern Med 237:221-227, 1995.
6. Zoller B, Svensson PJ, He X, Dahlback B: Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94:2521-2524, 1994.
7. Dahlback B: Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 24:139-151, 1994.
8. Bertina RM, Koeleman BP, Koster T, Resendaal FR, Dirven RJ, de Ronde H, Van der Velder PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67, 1994.
9. Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB: The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 270 20794-20800, 1995.
10. de Maat MP, Kluft C, Jesperson J, Gram J: World distribution of factor V FV R506Q Leiden. Lancet 347:58, 1996.
11. Schroder W, Koessling M, Wulff K, Wehnert M, Herrmann FH: World distribution of factor V FV R506Q Leiden. Lancet 347:58-59, 1996.
12. Fouere S, Guibal F, Morel P: World distribution of factor V FV R506Q Leiden. Lancet 347:59, 1996.
13. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 346:1133-1134, 1995.
14. Rosen S, Johansson K, Lindberg K, Dahlback B: Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals: The APC Resistance Study Group Thromb Haemost 72:255-260, 1994.
15. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR: High prevalence of a mutation in the factor V gene within the U.K. population: Relationship to activated protein C resistance and familial thrombosis. Br J Haematol 88:219-222, 1994.
16. Svensson PJ, Dahlback B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517-522, 1994.
17. Liu XY, Nelson D, Grant C, Morthland V, Goodnight SH, Press RD: Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C. Diagn Mol Pathol 4:191-197, 1995.
18. Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reitsma PH: Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol 49:242-243, 1995
19. Ma DD, Aboud MR, Williams BG, Isbister JP: Activated protein C resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic. Aust N Z J Med 25:151-154, 1995.
20. Kambayashi J, Fujimura H, Kawasaki T, Sakon M, Monden M, Suehisa E, Amino N: The incidence of activated protein C resistance among patients with deep vein thrombosis and healthy subjects in Osaka. Thromb Res 79:227-229, 1995.
21. Gou D, Naipal A, Reitsma PH: World distribution of factor V FV R506Q Leiden. Lancet 347:59, 1996.
22. Pottinger P, Sigurdsson F, Berliner N: Detection of the Factor V FV R506Q Leiden in a non-selected black population. Blood 87:2091, 1996.
23. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912-917, 1995.
24. Dahlback B: Molecular genetics of venous thromboembolism: Ann Med 27:187-192, 1995.
25. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504-1508, 1995.
26. Voorberg J, Roelse J, Koopman R, Buller H, Berends H Ten Cate JW, Mertens K, VanMoutik JA: Association of idiopathic venous thromboembolism with single point-mutation at arg 506 of Factor V. Lancet 343:1535-1536, 1994.
27. Dhote R, Bachmeyer C, Horellou MH, Toulon P, Christoforov B: Central retinal vein thrombosis associated with resistance to activated protein C. Am J Ophthalmol 120:388-389, 1995.
28. Petaja J, Jalanko H, Homberg C, Kinnunen S, Syrjala M: Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome. J Pediatr 127:103-105, 1995.
29. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 173:210-213, 1995.
30. Osterud B, Robertsen R, Asvang GB, Thijssen F: Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolysis 5:853-854, 1994.
31. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM. Rosendaal FR: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V FV R506Q Leiden mutation. Lancet 344:1453-1457, 1994.
32. Simioni P, deRonde H, Prandoni P, Saladini M, Bertina RM, Girolami A: Ischemic stroke in young patients with Activated Protein C Resistance: A report of three cases belonging to three different kindreds. Stroke 26:885-890, 1995.
33. Demarmels-Biasiutti F, Merlo C, Furlan M, Suzler I, Binder BR, Lammle B: No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis 6:456-459, 1995.
34. Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K: Evidence against heterozygous coagulation factor V 1691 G→A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med 73:521-524, 1995.
35. Press RD, Liu XY, Beamer N, Coull BM. Ischemic stroke in the elderly: Role of the common factor V mutation causing resistance to activated protein C. Stroke 27:44-48, 1996.
36. Machotka SV, Garrett CT, Schwartz AM, Callahan R: Amplification of the proto-oncogenes int-2, c-erb-2 and c-myc in human breast cancer. Clin Chim Acta 184:207-217, 1989.
37. Ferreira-Gonzalez A, DeAngelo AB, Nasim S, Garrett CT: Ras oneogene activation during hepatocarcinogenesis in B6C3F1 male mice by dichioroacetic and trichloroacetic acids. Carcinogenesis 16:495-500, 1995.
38. Le DT, Griffin JH, Greengard JS, Mujundar V, Rapaport SI: Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant Factor Va in patients receiving warfarin and in patients with lupus anticoagulant. Blood 85:1704-1711, 1995.